Management of penile dermatoses

Expert Review of Dermatology

Volumn 1, Issue 2, 2006, Pages 241-260

  Bunker, Christopher B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Bowen's disease of the penis; Bowenoid papulosis; circumcision; dysesthesia syndromes; dysfunctional foreskin; erosive lichen planus; erythroplasia of Queyrat; lichen sclerosus; male dyspareunia; nonspecific balanoposthitis; squamous carcinoma; Zoon's balanitis

Indexed keywords

EID: 35348897941     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.2.241     Document Type: Article

References (328)

1. Moses S, Bailey RC, Ronald AR. Male circumcision: assessment of health benefits and risks. Sex Transm. Infect. 74, 368–373 (1998).
2. Bunker CB. Male Genital Dermatology. Saunders, London, UK (2004).
3. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch. Dis. Child. 90, 853–858 (2005).
4. Van Howe RS. Effect of confounding in the association between circumcision status and urinary tract infection. J. Infect. 51, 59–68 (2005).
5. O’Farrell N, Egger M. Circumcision in men and the prevention of HIV infection: a ‘meta-analysis’ revisited. Int. J. STD AIDS 11, 137–142 (2000).
6. Bailey RC, Plummer FA, Moses S. Male circumcision and HIV prevention: current knowledge and future research directions. Lancet Infect. Dis. 1, 223–231 (2001).
7. Siegfried N, Muller M, Volmink J et al. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst. Rev. 3, CD003362 (2003).
8. Inungu J, Malone Beach E, Betts J. Male circumcision and the risk of HIV infection. AIDS Read. 15 (3), 130–131 (2005).
9. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2 (11), E298 (2005).
10. Mallon E, Hawkins D, Dinneen M et al. Circumcision and genital dermatoses. Arch. Dermatol. 136, 350–354 (2000).
11. Whitfield H. Circumcision. BJU Int. 83 (Suppl.1) 1–113 (1999).
12. Alanis MC, Lucidii RS. Neonatal circumcision: a review of the world’s oldest and most controversial operation. Obstet. Gynaecol. Surv. 59 (5), 379–395 (2004).
13. Hutcheson JC. Male neonatal circumcision: indications, controversies and complications. Urol. Clin. N. Am. 31, 461–467 (2004).
14. Benatar M, Benatar D. Between prophylaxis and child abuse: the ethics of neonatal male circumcision. Am. J. Bioeth. 3, 35–48 (2003).
15. Porter WM, Bunker CB. The dysfunctional foreskin. Int. J. STD AIDS 12, 216–220 (2001).
16. Mallon E, Ross JS, Hawkins DA, Dinneen M, Francis N, Bunker CB. Biopsy of male genital dermatoses. Genitour. Med. 73, 421 (2004).
17. Zoon JJ. Verenigingsverslagen. Nederl. Tijdschr. Geneeskd. 94, 1528–1530 (1950).
18. Zoon JJ. Balanoposthite chronique circonscrite benigne a plasmocytes. Dermatologica 105, 1–7 (1952).
19. Davis J, Shapiro L, Baral J. Vulvitis circumscripta plasmacellularis. J. Am. Acad. Dermatol. 8, 413–416 (1983).
20. Woodruff JD, Sussman J, Shakfeh S. Vulvitis circumscripta plasma cellularis. J. Reprod. Med. 34, 369–372 (1989).
21. Baughman RD, Berger P, Pringle WM. Plasma cell cheilitis. Arch. Dermatol. 110, 725–726 (1974).
22. White JW Jr, Olsen KD, Banks PM. Plasma cell orificial mucositis. Arch. Dermatol. 122, 1321–1324 (1986).
23. Yoganathan S, Bohl TG, Mason G. Plasma cell balanitis and vulvitis (of Zoon). J. Reprod. Med. 39, 939–944 (1994).
24. Altmeyer P, Kastner U, Luther H. Die Balanitis? Balanoposthitis chronica circumscripta benigna plasmacellularis-Entitat oder Fiktion? [Balanitis/balanoposthitis chronica circumscripta benignaplasmacellularis-entity or fiction]? Hautarzt 49, 552–555 (1998).
25. Cascajo C. Balanitis of Zoon: a clinicopathologic study of 45 cases. Am. J. Dermatopathol. 24, 459–467 (2002).
26. Kiene P, Folster-Holst R. No evidence of human papillomavirus infection in balanitis circumscripta plasmacellularis Zoon. Acta Derm. Venereol. 75, 496–497 (1995).
27. Kuniyuki S, Asada T, Yasumoto R. A case of vulvitis circumscripta plasmacellularis positive for herpes simplex Type II antigen. Clin. Exp. Dermatol. 23, 230–231 (1998).
28. Toonstra J, van Wichen DF. Immunohistochemical characterization of plasma cells in Zoon’s balanoposthitis and (pre) malignant skin lesions. Dermatologica 172, 77–81 (1986).
29. Nishimura M, Matsuda T, Muto M, Hori Y. Balanitis of Zoon. Int. J. Dermatol. 29, 421–423 (1998).
30. Farrell AM, Francis N, Bunker CB. Zoon’s balanitis: an immunohistochemical study. Br. J. Dermatol. 135 (Suppl. 47), 57 (1996).
31. Kumar B, Sharma R, Rajagopalan M, Radotra BD. Plasma cell balanitis: clinical and histopathological features–response to circumcision. Genitourin. Med. 71, 32–34 (1996).
32. Kossard S, Shumack S. Lichen aureus of the glans penis as an expression of Zoon’s balanitis. J. Am. Acad. Dermatol. 21, 804–806 (1998).
33. Bureau Y, Barriere H, Evin YP. Les erythroplasies benignes a plasmocytes. Ann. Dermatol. Syphilig. 89, 271–284 (1962).
34. Davis-Daneshfar A, Trueb RM. Bowen’s disease of the glans penis (erythroplasia of Queyrat) in plasma cell balanitis. Cutis 65, 395–398 (2000).
35. Dupre A, Bonafe J-L, Lassere J et al. Lesions bourgeonnantes pruputiales a plasmocytes: variante anatomo-clinique de la balano-posthite chronique circonscrite benigne de Zoon. Bulletin de la Societe Francaise Dermatologie et Syphiligraphie 83, 62–63 (1976).
36. Jonquieres EDL. Balanitis pseudoeritroplasicas. Archivos Argentinos de Dermatologica 21, 85–95 (1971).
37. Porter WM, Hawkins DA, Dinneen M, Bunker CB. Zoon’s balanitis and carcinoma of the penis. Int. J. STD AIDS 11, 484–485 (2002).
38. Sonnex TS, Dawber RPR, Ryan TJ, Ralfs IG. Zoon’s (plasma-cell) balanitis: treatment by circumcision. Br. J. Dermatol. 106, 585–588 (1982).
39. Tang A, David N, Horton LW. Plasma cell balanitis of Zoon: response to Trimovate cream. Int. J. STD AIDS 12, 75–78 (2001).
40. Santos-Juanes J, Sanchez del Rio J, Galache C, Soto J. Topical tacrolimus: an effective therapy for Zoon balanitis. Arch. Dermatol. 140, 1538–1539 (2004).
41. Hernandez-Machin B, Hernando LB, Marrero OB, Hernandez B. Plasma cell balanitis of Zoon treated successfully with topical tacrolimus. Clin. Exp. Dermatol. 30, 588–589 (2005).
42. Albertini JG, Holck DE, Farley MF. Zoon’s balanitis treated with Erbium: YAG laser ablation. Lasers Surg. Med. 30, 123–126 (2002).
43. Retamar RA, Kien MC, Chouela EN. Zoon’s balanitis: presentation of 15 patients, five treated with carbon dioxide laser. Int. J. Dermatol. 42, 305–307 (2003).
44. Itin PH, Hirsbrunner P, Buchner S. Lichen planus: an unusual cause of phimosis. Acta Dermato-Venereologica 72 (1), 41–42, (1992).
45. Aste N, Pau M, Ferreli C, Biggio P. Lichen planus in a child requiring circumcision. Pediatr. Dermatol. 14 (2), 129–130 (1997).
46. Cribier B, Ndiaye I, Grosshans E. Peno-gingival syndrome. A male equivalent of vulvo-vagino-gingival syndrome. Revue de Stomatologie et de Chirurgie Maxillo-Faciale 94 (3), 148–151 (1992).
47. Hahn JM, Meisler DM, Lowder CY, Tung RC, Camisa C. Cicatrizing conjunctivitis associated with paraneoplastic lichen planus. Am. J. Ophthalmol. 129 (1) 98–99 (2000).
48. Worheide J, Bonsmann G, Kolde G, Hamm H. Plattenepithyelkarzinom auf dem Boden eines lichen ruber hypertrophicus an der glans penis. Der Hautarzt 42 (2), 112–115 (1991).
49. Leal-Khouri S, Hruza GJ. Squamous cell carcinoma developing within lichen planus of the penis. Treatment with Mohs micrographic surgery. J. Dermatol. Surg. Oncol. 20 (4), 272–276 (1994).
50. Jemec GBE, Baadsgaard O. Effect of cyclosporin on genital psoriasis and lichen planus. A randomised trial of simple excision of non-specific hypertrophied anal papillae versus expectant management in patients with chronic pruritus ani. Ann. R. Col. Surg. (England) 70, 348–349 (1988).
51. Schmitt EC, Pigatto PD, Boneschi V, Bigardi AS, Finzi AF. Erosiver lichen planus der glans penis. Der Hautarzt 44 (1), 43–45 (1993).
52. Kirby B, Whitehurst C, Moore JV, Yates VM. Treatment of lichen planus of the penis with photodynamic therapy. Br. J. Dermatol. 141 (4), 765–766 (1999).
53. Porter WM, Dinneen M, Hawkins DA, Bunker CB. Erosive penile lichen planus responding to circumcision. JEADV 15, 266–268 (2001).
54. Perceau G, Derancourt C, Clavel C et al. Lichen sclerosus is frequently present in penile squamous cell carcinoma but is not always associated with oncogenic human papillomavirus. Br. J. Dermatol. 148, 934–938 (2003).
55. Velazquez EF, Cubilla AL. Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: frequent atypias and correlation with special carcinoma variants suggests a precancerous role. Am. J. Surg. Pathol. 27, 1148–1153 (2003).
56. Ritchie AWS, Foster PW, Fowler S. Penile cancer in the UK: clinical presentation and outcome in 1998/99. BJU Int. 94, 1248–1252 (2004).
57. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 353, 1777–1783 (1999).
58. English JC III, King DH, Foley JP. Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction. J. Am. Acad. Dermatol. 39, 801–803 (1998).
59. Mattioli G, Repetto P, Carlini C, Granata C, Gambini C, Jasonni V. Lichen sclerosus et atrophicus in children with phimosis and hypospadias. Pediatr. Surg. Int. 18, 273–275 (2002).
60. Weigand DA. Microscopic features of lichen sclerosus et atrophicus in acrochordons: a clue to the cause of lichen sclerosus et atrophicus? J. Am. Acad. Dermatol. 28, 751–754 (1993).
61. Wallace HJ. Lichen sclerosus et atrophicus. Trans. St John’s Dermatol. Soc. 57, 9–30 (1971).
62. Goolamali SK, Barnes EN, Irvine WJ et al. Organ-specific antibodies in patients with lichen sclerosus. BMJ iv: 78–79 (1974).
63. Harrington Cl, Dunsmore IR. An investigation into the incidence of autoimmune disorders in patients with lichen sclerosus et atrophicus. Br. J. Dermatol. 104, 563–566 (1981).
64. Meyrick Thomas RH, Ridley CM, Black MM. The association of lichen sclerosus et atrophicus and autoimmune-related disease in males. Br. J. Dermatol. 109, 661–664 (1983).
65. Tremaine RDL, Miller RAW. Lichen sclerosus et atrophicus. Int. J. Dermatol. 28, 10–16 (1989).
66. Vaccaro M, Guarneri F, Borgia F, Cannavo SP, Benvenga S. Association of lichen sclerosus and autoimmune thyroiditis: possible role of borrelia burgdorferi? Thyroid 12, 1147–1148 (2002).
67. Azurdia RM, Luzzi GA, Byren I et al. Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease. Br. J. Dermatol. 140, 79–83 (1999).
68. Senturk N, Aydin F, Birinci A et al. Coexistence of HLA-B*08 and HLA-B*18 in four siblings with lichen sclerosus. Dermatology 208, 64–66 (2004).
69. Hinchliffe SA, Ciftci AO, Rickwood AMK et al. Compostion of the inflammatory infiltrate in pediatric penile lichen sclerosus and atrophicus (balanitis xerotica obliterans). Pediatr. Pathol. 14, 223–233 (1994).
70. Farrell AM, Marren P, Dean D, Wojnarowska F. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin. Br. J. Dermatol. 140, 1087–1092 (1999).
71. Regauer S, Liegl B, Reich O, Beham-Schmid C. Vasculitis in lichen sclerosus: an under recognized feature? Histopathology 45, 237–244 (1995).
72. Regauer S, Reich O, Beham-Schmid C. Monoclonal γ-T-cell receptor rearrangement in vulvar sclerosus and squamous cell carcinoma. Am. J. Pathol. 160, 1035–1045 (2002).
73. Tchorzewski H, Rotsztejn H, Banasik M, Lewkowicz P, Glowacka E. The involvement of immunoregulatory T-cells in the pathogenesis of lichen sclerosus. Med. Sci. Monit. 11, CR39–CR43 (2005).
74. Regauer S. Immune dysregulation in lichen sclerosus. Eur. J. Cell Biol. 84, 273–277 (2005).
75. Aberer E, Neumann R, Lubec G. Acrodermatitis chronica atrophicans in association with lichen sclerosus et atrophicans: tubulo-interstitial nephritis and urinary excretion of spirochete-like organisms. Acta Derm. Venereol. (Stockh.) 67, 62–91 (1987).
76. Schempp C, Bocklage H, Lange R, Kölmel HW, Orfanos CE. Further evidence for borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J. Invest. Dermatol. 100, 717–720 (1993).
77. Foldes-Papp Z, Reich O, Demel U, Tilz GP. Lack of specific immunological disease pattern in vulvar lichen sclerosus. Exp. Mol. Pathol. 79, 176–185 (2005).
78. Drut RM, Gomez MA, Drut R, Lojo MM. Human papillomavirus is present in some cases of childhood penile lichen sclerosus: an in situ hybridization and SP-PCR study. Pediatr. Dermatol. 15, 85–90 (1998).
79. Farrell AM, Millard PR, Schomberg KH, Wojnarowska F. An infective aetiology for lichen sclerosus re-addressed. Clin. Exp. Dermatol. 24, 479–483 (1999).
80. Oyama N, Chan I, Neill SM et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 362 (9378), 118–123 (2003).
81. Edmonds EV, Chan I, Pyama N et al. Autoantibodies to extracellular matrix protein 1 in male genital lichen sclerosus. J. Invest. Dermatol. 124 (Suppl.) (2005).
82. Sander CS, Ali I, Dean D, Thiele JJ, Wojnarowska F. Oxidative stress is implicated in the pathogenesis of lichen sclerosus. Br. J. Dermatol. 151, 627–635 (2004).
83. Chalmers RJG, Burton PA, Bennett RF, Goring CC, Smith PJB. Lichen sclerosus et atrpohicus. Arch. Dermatol. 120, 1025–1027 (1984).
84. Rickwood AM, Hemalatha V, Batcup G, Spitz L. Phimosis in boys. Br. J. Urol. 52, 147–150 (1980).
85. Ridley CM. Genital lichen sclerosus (lichen sclerosus et atrophicus) in childhood and adolescence. J. R. Soc. Med. 86, 69–75 (1993).
86. Meuli M, Brinker J, Hanimann B, Sacher P. Lichen sclerosus and atrophicus causing phimosis in boys: a prospective study with 5-year follow-up after complete circumcision. J. Urol. 152, 987–989 (1994).
87. Clemmensen OJ, Krogh J, Petri M. The histologic spectrum of prepuces from patients with phimosis. Am. J. Dermatopathol. 10, 104–108 (1988).
88. Aynaud O, Piron D, Casanova JM. Incidence of preputial lichen sclerosus in adults: histologic study of circumcision specimens. J. Am. Acad. Dermatol. 41, 923–926 (1999).
89. Ridley CM, Neill SM. Circumcision. BMJ 306 (6877), 583–584 (1993).
90. Barbagli G, Palminteri E, Balo S et al. Lichen sclerosus of the male genitalia and urethral stricture diseases. Urol. Int. 73, 1–5 (2004).
91. Jenny C, Kirby P, Fuquay D. Genital lichen sclerosus mistaken for child sexual abuse. Pediatrics 83, 597–599 (1989).
92. Loening-Baucke V. Lichen sclerosus and atrophicus in children. Am. J. Dis. Child. 145, 1058–1061 (1991).
93. Al-Khenaizan S, Almuneef M, Kentab O. Lichen sclerosus mistaken for child sexual abuse. Int. J. Dermatol. 44, 317–320 (2005).
94. Berth-Jones J, Graham-Brown RA, Burns DA. Lichen sclerosus. Arch. Dis. Child. 64, 1204–1206 (1989).
95. Harrington CI. Lichen sclerosus. Arch. Dis. Child. 65, 335 (1990).
96. Tasker GL, Wojnarowska F. Lichen sclerosus. Clin. Exp. Dermatol. 28, 128–133 (2003).
97. Neill SM, Tatnall FM, Cox NH. British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br. J. Dermatol. 147, 640–649 (2002).
98. Dahlman-Ghozlan K, Hedblad MA, von Krogh G. Penile lichen sclerosus and atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. J. Am. Acad. Dermatol. 40, 451–457 (1999).
99. Lindhagen T. Topical clobetasol propionate compared with placebo in the treatment of unretractable foreskin. Eur. J. Surg. 162, 969–972 (1996).
100. Jorgensen ET, Svensson A. Problems with the penis and prepuce in children. Lichen sclerosus should be treated with corticosteroids to reduce need for surgery. BMJ 313, 692 (1996).
101. Pasieczny TAH. The treatment of balanitis xerotica obliterans with testosterone propionate ointment. Acta. Dermato-Venereologica 57, 275–277 (1977).
102. Heise H, Flegel H, Helmke R. Treatment of lichen sclerosus and atrophicus with testosterone propionate ointment. Dermatol. Monatssch. 170, 135–138 (1984).
103. Skierlo P, Heise H. Testosterone propionate ointment – a therapeutic trial in lichen sclerosus et atrophicus. Hautarzt 38, 295–297 (1987).
104. Virgili A, Corazza M, Bianchi A, Mollica G, Califano A. Open study of topical 0.025% tretinoin in the treatment of vulval lichen sclerosus. One year of therapy. J. Reprod. Med. 40, 614–618 (1995).
105. Kaya G, Saurat JH. Restored epidermal CD44 expression in lichen sclerosus and atrophicus and clinical improvement with topical application of retinaldehyde. Br. J. Dermatol. 152, 570–572 (2005).
106. Reichrath J, Reinhold U, Tilgen W. Treatment of genito-anal lesions in inflammatory skin diseases with PUVA cream photochemotherapy: an open pilot study in 12 patients. Dermatology. 205, 245–248 (2002).
107. Bohm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch. Dermatol. 139, 922–924 (2003).
108. Kunstfeld R, Kirnbauer R, Stingl G, Karlhofer FM. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch. Dermatol. 39, 850–852 (2003).
109. Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J. Am. Acad. Dermatol. 48, 935–937 (2003).
110. Pandher BS, Rustin MH, Kaisary AV. Treatment of balanitis xerotica obliterans with topical tacrolimus. J. Urol. 17, 923 923 (2003).
111. Marini A, Blecken S, Ruzicka T, Hengge UR. Lichen sclerosus. New aspects of pathogenesis and treatment. Hautarzt. 56, 550–555 (2005).
112. Bunker CB, Neill S, Staughton RCD. Topical tacrolimus, genital lichen sclerosus and risk of squamous cell carcinoma. Arch. Dermatol. 140, 1169 (2004).
113. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br. J. Dermatol. 152, 176–198 (2005).
114. Shelley WB, Shelley ED, Grunenwald MA et al. Long-term antibiotic therapy for balanitis xerotica obliterans. J. Am. Acad. Dermatol. 40, 69–72 (1999).
115. Parsad D, Saini R. Oral stanozolol in lichen sclerosus et atrophicus. J. Am. Acad. Dermatol. 38, 278–279 (1998).
116. Ronger S, Viallard AM, Meunier-Mure F, Chouvet B, Balme B, Thomas L. Oral calcitriol: a new therapeutic agent in cutaneous lichen sclerosus. J. Drugs Dermatol. 2, 23–28 (2003).
117. Neuhofer J, Fritsch P. Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm. Venereol. 64, 171–174 (1984).
118. Yokota M, Mizuno N. A case of lichen sclerosus et atrophicus of the vulva effectively treated with oral etretinate. J. Dermatol. 15, 330–333 (1988).
119. Bousema MT, Romppanen U, Gieger JM et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 30, 225–231 (1994).
120. Meyrick Thomas RH, Ridley CM, Black MM. Clinical features and therapy of lichen sclerosus et atrophicus affecting males. Clin. Exp. Dermatol. 12, 126–128 (1987).
121. Happle R. Chirurgische Behandlung des Lichen sclerosus et atrophicus penis. [Surgical treatment of penile lichen sclerosus et atrophicus]. Dermatol. Monatssch. 159, 975–977 (1973).
122. Campus GV, Ena P, Scuderi N. Surgical treatment of balanitis xerotica obliterans. Plast. Reconstr. Surg. 73, 652–657 (1984).
123. Peterson AC, Palminteri E, Lazzeri M, Guanzoni G, Barbagli G, Webster GD. Heroic measures may not always be justified in extensive urethral stricture due to lichen sclerosus (balanitis xerotica obliterans). Urology 64, 565–568 (2004).
124. Barbagli G, Palminteri E, Bracka A, Caparros Sariol J. Penile urethral reconstruction: concepts and concerns. Arch. Esp. Urol. 56, 549–556 (2003).
125. Lee SJ, Phillips SM. Recurrent lichen sclerosus et atrophicus in urethroplasties from multiple skin grafts. Br. J. Urol. 74, 802–803 (1994).
126. 2 laser for therapeutic circumcision in adults. Eur. Urol. 28, 74–76 (1995).
127. Hrebinko RL. Circumferential laser vaporization for severe meatal stenosis secondary to balanitis xerotica obliterans. J. Urol. 156, 1735–1736 (1996).
128. Kartamaa M, Reitamo S. Treatment of lichen sclerosus with carbon dioxide laser vaporization. Br. J. Dermatol. 136, 356–359 (1997).
129. Ridley CM. Lichen sclerosus et atrophicus. Arch. Dermatol. 123, 457–460 (1987).
130. Schnitzler L, Sayag J, Sayag J et al. Epitheliome spino-cellulaire aign de la verge et lichen sclero-atrophique. Ann. Dermatol. Venereol. 114, 979–981 (1987).
131. Weber P, Rabinovitz H, Garland L. Verrucous carcinoma in penile lichen sclerosus et atrophicus. J. Dermatol. Surg. Oncol. 13, 529–532 (1987).
132. Campus GV, Alia F, Bosincu L. Squamous cell carcinoma and lichen sclerosus et atrophicus of the prepuce. Plast. Reconst. Surg. 89, 962–964 (1992).
133. Simonart T, Noel JC, De Dobbeleer G, Simonart JM. Carcinoma of the glans penis arising 20 years after lichen sclerosus. Dermatology 196, 337–338 (1998).
134. Paricio, Rubio JF, Revenga AF, Alfaro TJ, Ramirez GT. Squamous cell carcinoma of the penis arising on lichen sclerosus et atrophicus. J. Eur. Acad. Dermatovenereol. 12, 153–156 (1999).
135. Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J. Am. Acad. Dermatol. 41, 911–914 (1999).
136. Micali G, Nasca MR, Innocenzi D. Lichen sclerosus of the glans is significantly associated with penile carcinoma. Sex Transm. Infect. 77, 226 (2001).
137. Cubilla AL, Velazquez EF, Young RH. Pseudohyperplastic squamous cell carcinoma of the penis associated with lichen sclerosus. An extremely well-differentiated, non-verruciform neoplasm that preferentially affects the foreskin and is frequently misdiagnosed: a report of 10 cases of a distinctive clinicopathologic entity. Am. J. Surg. Pathol. 28, 895–900 (2004).
138. Pinto AP, Lin MC, Sheets EE, Muto MG, Crum CP. Allelic imbalance in lichen sclerosus, hyperplasia and intraepithelial neoplasia of the vulva. Gynecol. Oncol. 77, 171–176 (2000).
139. Maden C, Sherman KJ, Beckmann AM et al. History of circumcision, medical conditions, and sexual activity and the risk of penile cancer. J. Natl Cancer Inst. 85, 19–24 (1993).
140. Holly EA, Palefsky JM. Factors related to risk of penile cancer: New evidence from a study in the Pacific northwest. J. Natl Cacer Inst. 85, 2–3 (1993).
141. Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, Dubertret L. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch. Dermatol. 140, 709–712 (2004).
142. Von Krogh G, Dahlman-Ghozlan K, Syrjanen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J. Eur. Acad. Dermatol. Venereol. 16, 130–133 (2002).
143. Bouyssou-Gauthier ML, Boulinguez S, Dumas JP, Bedane C, Bonnetblanc JM. Lichen sclereux genital masculin: etude de suivi. [Penile lichen sclerosus: follow-up study]. Ann. Dermatol. Venereol. 126, 804–807 (1999).
144. Liatsikos EN, Perimenis P, Dandinis K, Kaladelfou E, Barbalias G. Lichen sclerosus et atrophicus. Findings after complete circumcision. Scand. J. Urol. Nephrol. 31, 453–456 (1997).
145. Hunt SJ, Francis N, Dinneen M, Hawkins D, Bunker CB. A retrospective study of 174 men with lichen sclerosus of the penis. Br. J. Dermatol. 149 (Suppl), 53–54 (2003).
146. Yesudian PD, Sugunendran H, Bates CM, O’Mahony C. Lichen sclerosus. Int. J. STD AIDS 16, 465–473 (2005).
147. Bunker CB. Diagnosis and management of penile pre-cancer: combined clinics and topical chemotherapy. In: The Effective Management of Urological Malignancies. Anderson J, Oliver RTD, Miles A (Eds). Aesculapius Medical Press, London, UK (2005).
148. Edwards S. Balanitis and balanoposthitis: a review. Genitourin. Med. 72, 155–159 (1996).
149. English JC III, Laws RA, Keough GC, Wilde JL, Foley JP, Elston DM. Dermatoses of the glans penis and prepuce. J. Am. Acad. Dermatol. 37, 1–24 (1997).
150. Fornasa CV, Calabro A, Miglietta A, Tarantello M, Biasinutto C, Peserico A. Mild balanoposthitis. Genitourin. Med. 70, 345–346 (1994).
151. Birley HDL, Walker MM, Luzzi GA et al. Features and management of recurrent balanitis; association with atopy and genital washing. Genitourinary Med. 69, 400–403 (1993).
152. Chopra R, Fisher RD, Fencel R. Phimosis and diabetes mellitus. J. Urol. 127, 1101–1102 (1982).
153. Alessi E, Coggi A, Gianotti R. Review of 120 biopsies performed on the balano-preputial sac. from Zoon’s balanitis to the concept of a wider spectrum of inflammatory non-cicatricial balanoposthitis. Dermatology 208, 120–124 (2004).
154. Edwards SK. European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of balanoposthitis. Int. J. STD AIDS 12, 68–72 (2001).
155. Cotterill JA. A dermatological non-disease – a common and potentially fatal disturbance of cutaneous body image. Br. J. Dermatol. 103 (Suppl. 18), 13 (1980).
156. Markos AR. The male genital skin burning syndrome (dysaesthetic peno/scroto-dynia). Int. J. STD AIDS 13 (4), 271–272 (2002).
157. Parks AG, Porter NH, Hardcastle J. The syndrome of descending perineum. Proc. R. Soc. Med. 59, 477–482 (1966).
158. Lask, D, Kimche D. Congenital polyp of the prostatic urethra. J. Urol. 127 (1), 134 (1982).
159. Neill ME, Swash M. Chronic perianal pain: an unsolved problem. J. R. Soc. Med. 75, 96–101 (1982).
160. Wesselmann U, Burnett AL, Heinberg LJ. The urogenital and rectal pain syndromes. Pain 73, 269–294 (1997).
161. Fisher BK. The red scrotum syndrome. Cutis 60, 139–141 (1997).
162. Feler CA, Whitworth LA, Fernandez J. Sacral neuromodulation for chronic pain conditions. Anesthesiol. Clin. N. Am. 21, 785–795 (2003).
163. Carter JE. A systematic history for the patient with chronic pelvic pain. JSLS 3, 245–252 (1999).
164. Morrissette DL, Goldstein MK, Raskin DB, Rowland DL. Finger and penile tactile sensitivity in sexually functional and dysfunctional diabetic men. Diabetologia 42, 336–342 (1999).
165. Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynaecol. Obstet. Invest. 58, 164–167 (2004).
166. Cohen AD, Vander T, Medvendovsky E et al. Neuropathic scrotal pruritus: anogenital pruritus is a symptom of lumbosacral radiculopathy. J. Am. Acad. Dermatol. 52, 61–66 (2005).
167. Bunker CB, Bridgett CK, Depression and the skin. In: Depression and Physical Illness (Perspectives in Psychiatry). Robertson MM, Katona CLE (Eds), John Wiley and son Ltd, UK (1997).
168. Pietrzak P, Watkin N. Modern management of penile cancer. In: The Effective Management of Urological Malignancies. Anderson J, Oliver RTD, Miles A (Eds). Aesculapius Medical Press, London, UK (2005).
169. Hamid R, Chergill I, Arya M, Patel HR. Penile cancer: an overview. Hosp. Med. 63, 718–721 (2002).
170. Droller MJ. Carcinoma of the penis: an overview. Urol. Clin. N. Am. 7, 783–784 (1980).
171. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 5, 240–247 (2004).
172. Frisch M, Friis S, Kjaer SK, Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943–90). Br. Med. J. 311, 1471 (1995).
173. Markos AR. The management of penile intraepithelial neoplasia in genitourinary med. Int. J. STD AIDS 14, 314–319 (2003).
174. Graham JH, Helwig EB. Bowen’s disease and its relationship to internal malignancy. Arch. Dermatol. 80, 133–159 (1959).
175. Graham JH, Mazzanti GR, Helwig EB. Chemistry of Bowen’s disease: relationship to arsenic. J. Invest. Dermatol. 37, 317–329 (1961).
176. Graham JH, Helwig EB. Erythroplasia of Queyrat: a clinicopathologic and histochemical study. Cancer 32, 1396–1414 (1977).
177. Gerber GS. Carcinoma in situ of the penis. J. Urol. 151, 829–833 (1994).
178. Bowen JT. Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J. Cut. Dis. 30, 241–254 (1912).
179. Reed DC. Erythroplasia of Queyrat: an unusual instance in a Negro patient involving the penis and progressing to invasive carcinoma. J. Kans. Med. Soc. 57, 482–484 (1956).
180. Milstein HG. Erythroplasia of Queyrat in a partially circumcised man. J. Am. Acad. Dermatol. 10, 398 (1982).
181. McAninch JW, Moore CA. Precancerous penile lesions in young men. J. Urol. 104, 287–290 (1970).
182. Yasuda M, Tamura A, Shinizu A, Takahashi A, Ishikawa O. Bowen’s disease involving the urethra. J. Dermatol. 32, 210–213 (2005).
183. Lloyd KM. Multicentric pigmented Bowen’s disease of the groin. Arch. Dermatol. 101, 48–51 (1970).
184. Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the genitalia. Arch. Dermatol. 115, 306–308 (1979).
185. Schwartz RA, Janniger CK. Bowenoid papulosis. J. Am. Acad. Dermatol. 24, 261–263 (1991).
186. Paget J. On disease of the mammary areola preceding carcinoma of the mammary gland. St Bartholomew’s Hospital Reports 10, 87–89 (1874).
187. Fournier A, Darier J. Epithelioma benin syphiloide de la verge (epitheliome papilllaire) Bulletin de la Societe Francaise Dermatologie et Syphigraphie 4, 324 (1893).
188. Morestin H. Deux cas de cancer du penis. Bulletin Societe Anatomie Paris 5, 387 (1903).
189. Queyrat L. Erythroplasie du gland. Bulletin de la Societe Francaise Dermatologie et Syphigraphie 22, 378–382 (1911).
190. Blau S, Hyman AB. Erythroplasic of Queyrat. Acta Derm. Venereol. 35, 341–378 (1955).
191. Cubilla AL, Meijer CJLM, Young RH. Morphological features of epithelial abnormalities and precancerous lesions of the penis. Scand. J. Urol. Nephrol. 205 (Suppl), 215–219 (2000).
192. Cubilla AL, Velazquez EF, Young RH. Epithelial lesions associated with invasive penile squamous cell carcinoma: a pathologic study of 288 cases. Int. J. Surg. Pathol. 12, 351–364 (2004).
193. Niederauer HH, Weindorf N, Schultz-Ehrenburg U. A case of giant condyloma acuminatum. On differential diagnosis of giant condylomas from Buschke-Lowenstein tumors and verrucous carcinoma. Hautarzt 44, 795–799 (1993).
194. Noel JC, Vandenbossche M, Peny MO et al. Verrucous carcinoma of the penis: importance of human papillomavirus typing for diagnosis and therapeutic decision. Eur. Urol. 22, 83–85 (1992).
195. Gonzalez-Lopez A, Esquivias JI, Miranda-Romero A, Massa CF, Tejerina JA. Buschke-Lowenstein tumor and immunity. Cutis 59, 119–122 (1997).
196. Anadolu R, Boyvat A, Calikoglu E, Gurler A. Buschke-Loewenstein tumour is not a low-grade carcinoma but a giant verucca. Acta. Derm. Venereol. 79, 253–254 (1999).
197. Haycox CL, Kuypers J, Krieger JN. Role of human papillomavirus typing in diagnosis and clinical decision making for a giant verrucous genital lesion. Urology 53, 627–630 (1999).
198. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med. Microbiol. Immunol. (Berl.). 193, 35–44 (2004).
199. Cubilla AL, Velazques EF, Reuter VE, Oliva E, Mihm MC Jr, Young RH. Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of ‘verruciform’ penile tumours. Am. J. Surg. Pathol. 24, 505–512 (2000).
200. Bezerra AL, Lopes A, Landman G, Alencar GN, Torlonii H, Villa LL. Clinicopathologic features and human papillomavirus DNA prevalence of warty and squamous cell carcinoma of the penis. Am. J. Surg. Pathol. 25, 673–678 (2001).
201. McKenna KE, Patterson CC, Handley J, McGinn S, Allen G. Cutaneous neoplasia following PUVA therapy for psoriasis. Br. J. Dermatol. 134, 639–642(1996).
202. Yoneta A, Yamashita T, Jin HY, Iwasawa A, Kondo S, Jimbow K. Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from Bowenoid papulosis. Br. J. Dermatol. 143, 604–608 (2000).
203. Eisen RF, Bhawan J, Cahn TH. Spontaneous regression of Bowenoid papulosis of the penis. Cutis 32, 269–272 (1983).
204. Wolbarst AL. Circumcision and penile cancer. Lancet 1, 150–153 (1932).
205. Schrek R, Lenowitz H. Etiological factors in carcinoma of the penis. Cancer Res. 7, 180–187 (1947).
206. Tsen HE, Morgenstern H, Mack T, Peters RK. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 12, 267–277 (2001).
207. Melmed EP, Payne JR. Carcinoma of the penis in a Jew circumcised in infancy. Br. J. Surg. 54, 729–731 (1967).
208. Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol. Clin. N. Am. 19, 227–246 (1992).
209. Muir CS, Nectoux J. Epidemiology of carcinoma of the testis and penis. USA Natl Cancer Inst. Monographs 53, 157–164 (1979).
210. Reddy CRRM, Devendranath V, Pratap S. Carcinoma of the penis: role of phimosis. Urology 24, 85–88 (1984).
211. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand. J. Urol. Nephrol. 205 (Suppl.), 189–193 (2000).
212. Hellberg D, Valentin J, Eklund T et al. Penile cancer: is there an epidemiological role for smoking and sexual behaviour. Br. Med. J. 295, 1306–1308 (1987).
213. Selli C, Scott CA, De Antoni P, Moro U, Crisci A, Cartei G. Squamous cell carcinoma arising at the base of the penis in a burn scar. Urology 54, 923 (1999).
214. Ciancio SJ, Coburn M. Penile salvage for squamous cell carcinoma associated with mineral oil injection. J. Urol. 164, 1650 (2000).
215. Daling JR, Madeleine MM, Johnson LG et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int. J. Cancer 116, 606–616 (2005).
216. Moore TO, Moore AY, Carrasco D et al. Human papillomavirus, smoking and cancer. J. Cutan. Med. Surg. 5, 323–328 (2001).
217. Sasson IM, Haley NJ, Hoffman D, Wynder EL et al. Cigarette smoking and neoplasia of the uterine cervix: smoke constituents incervical mucus. N. Engl. J. Med. 312, 315–316 (1985).
218. Winkelstein W Jr. Smoking and cancer of the uterine cervix. Am. J. Epidemiol. 106, 257–259 (1977).
219. Castonguay A, Tjdve H, Hecht SS. Tisue distribution of the the tobacco specific carcinogen4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its metabolites in F344 rats. Cancer Res. 43, 630–638 (1983).
220. Previte SR, Karian S, Cho SI, Austen G. Penile carcinoma in renal transplant recipient. Urology 13, 298–299 (1979).
221. Stern RS. Genital tumours among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. N. Engl. J. Med. 322, 1093–1097 (1990).
222. Perkins W, Lamont D, MacKie RM. Cutaneous malignancy in males treated with photochemotherapy. Lancet 336 (8725), 1248 (1990).
223. de la Brassinne M, Richert B. Genital squamous cell carcinoma after PUVA therapy. Dermatology 185, 316–318 (1992).
224. Fryrear RS, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J. Am. Acad. Dermatol. 51, 1026 (2004).
225. Poblet E, Alfaro L, Fernander-Segoviano P, Jimenez-Reyes J, Salido EC. Human papillomavirus-associated penile squamous cell carcinoma in HIV positive patients. Am. J. Surg. Pathol. 23, 1119–1123 (1999).
226. Gomousa-Michael M, Gialama E, Gomousas N, Gialama G. Genital human papillomavirus infection and associated penile intraepithelial neoplasia in males infected with the human immunodeficiency virus. Acta Cytol. 44, 305–309 (2000).
227. Aboulafia DM, Gibbons R. Penile cancer and human papilloma virus (HPV) in a human immunodeficiency virus (HIV)-infected patient. Cancer Invest. 19, 266–272 (2001).
228. Theodore C, Androulakis N, Spatz A, Goujard C, Blanchet P, Wilbault P. An explosive course of squamous cell penile cancer in an AIDS patient. Ann. Oncol. 13, 475–479 (2002).
229. Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch. Pathol. Lab. Med. 127, 589–592 (2003).
230. Keerti VS. Human papillomaviruses and anogenital cancers. N. Engl. J. Med. 337, 1386–1387 (1997).
231. Smith PG, Kinlen LJ, White GC et al. Mortality of wives of men dying with cancer of the penis. Br. J. Cancer 41, 422–428 (1980).
232. Barrasso R, De Brux J, Croissant O, Orth G. High prevalence of papillomavirus associated penile intraepithelial neoplasia in partners of women with cervical intraepithelial neoplasia. N. Engl. J. Med. 317, 916–923 (1987).
233. Kennedy L, Buntine DW, O’Connor D, Frazer IH. Human papillomavirus – a study of male sexual partners. Med. J. Aust. 149, 309–311 (1988).
234. Zabbo A, Stein BS. Penile intraepithelial neoplasia in patients examined for exposure to human papilloma virus. Urology 41, 24–26 (1993).
235. Ikenberg H, Gissmann L, Gross G, Grussendorf-Cohen EI, zur Hausen H. Human papillomavirus Type 16 DNA in genital Bowen’s disease and in Bowenoid papulosis. Int. J. Cancer 32, 563–565 (1983).
236. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurien W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3, 1151–1157 (1984).
237. Durst M, Kleinheinz A, Hotz M, Gissmann L. The physical state of human papillomavirus Type 16 DNA in benign and malignant genital tumours. J. Gen. Virol. 6, 1515–1522 (1985).
238. Dianzani C, Bucci M, Pierangelli A, Calvieri S, Degener AM. Association of human papillomavirus Type 11 with carcinoma of the penis. Urology 51, 1046–1048 (1998).
239. Inagaaki H, Nonaka M, Eimoto T. Bowenoid papulosis showing polyclonal nature. Diagn. Mol. Pathol. 70, 122–126 (1998).
240. Meyer T, Arndt R, Christophers E et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J. Infect. Dis. 178, 252–255 (1998).
241. Loning T, Riviere A, Henke RP, von Preyss S, Dorner A. Penile/anal condylomas and squamous cell cancer. A HPV DNA hybridization study. Virchows Arch. 413, 491–498 (1988).
242. Griffiths TRL, Mellon JK. Human papillomavirus and urological tunours: basic science and role in penile cancer. BJU Int. 84, 579–586 (1999).
243. Wieland U, Jurk S, Weissenborn S et al. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus Type 8 and genital papillomaviruses in a carcinoma in situ. J. Invest. Dermatol. 115, 396–401 (2000).
244. Salazar EL, Mercado E, Calzada L. Human papillomavirus hpv-16 DNA as an epitheliotropic virus that induces hyperproliferation in squamous penile tissue. Arch. Androl. 51, 327–334 (2005).
245. Buonaguro FM, Tornesello ML, Salatiello I. The Uganda study on HPV variants and genital cancers. J. Clin. Virol. 19, 31–41 (2000).
246. Suzuki H, Sato N, Kodama T et al. Detection of human papillomavirus DNA and state of p53 gene in Japanese penile cancer. Jpn. J. Clin. Oncol. 24, 1–6 (1994).
247. Rubin MA, Kleter B, Zhou M et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am. J. Pathol. 159, 1211–1218 (2001).
248. Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 91, 2315–2321 (2001).
249. Dillner J, Meijer CJ, von Krogh G, Horenblas S. Epidemiology of human papillomavirus infection. Scand. J. Urol. Nephrol. 205 (Suppl.), 194–200 (2000).
250. Perez VG, Eres Saez FJ, Ramada Benlloch FJ et al. Association of giant condyloma acuminatum of the penis with intraurethral simple condylomata. Apropos of a case. Arch. Espanol. Urol. 44, 1103–1105 (1991).
251. Noel JC, Vandenbossche M, Peny MO et al. Verrucous carcinoma of the penis: importance of human papillomavirus typing for diagnosis and therapeutic decision. Eur. Urol. 22, 83–85 (1992).
252. Boshart M, zur Hausen H. Human papillomaviruses in Buschke-Lowenstein tumours: physical state of the DNA and identification of a tandem duplification in the noncoding region of a human papillomavirus 6 subtype. J. Virol. 58, 963–966 (1986).
253. Grassegger A, Hopfl R, Hussl H, Wicke K, Fritsch P. Buschke-Loewenstein tumour infiltrating pelvic organs. Br. J. Dermatol. 130, 221–225 (1994).
254. O’Gorman-Lalor O, Walker NPJ, Mathews S, Francis N, Dinneen M, Bunker CB. Successful treatment of Buschke-Lowenstein tumour of the penis with carbon dioxide laser vaporisation. Clin. Exp. Dermatol. (In Press).
255. Heyns CF, van Vollenhoven P, Steenkamp JW, Allen FJ. Cancer of the penis – a review of 50 patients. S. Afr. J. Surg. 35, 120–124 (1997).
256. Lalla SC, Aldridge RD, Tidman MJ. Carcinoma of the penis presenting with dermatomyositis. Clin. Exp. Dermatol. 26, 558 (2001).
257. Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL. Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int. J. Surg. Pathol. 12, 139–146 (2004).
258. Cubilla AL, Reuter V, Velazquez E, Piris A, Saito S, Young RH. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int. J. Surg. Pathol. 9, 111–120 (2001).
259. Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL. Sarcomatoid carcinoma of the penis: a clinicopathological study of 15 cases. Am. J. Surg. Pathol. 29, 1152–1158 (2005).
260. Cubilla AL, Piris A, Pfanni R, Rodriguez I, Aguero F, Young RH. Anatomic levels: important landmarks in penectomy specimens: a detailed anatomic and histologic study based on examination of 44 cases. Am. J. Surg. Pathol. 25, 1091–1094 (2001).
261. Ono Y, Ozawa M, Tamura Y et al. Tumor-associated tissue eosinophilia of penile cancer. Int. J. Urol. 9, 82–87 (2002).
262. Berdjis N, Meye A, Nippgen J et al. Expression of Ki-67 in squamous cell carcinoma of the penis. BJU Int. 96, 146–148 (2005).
263. Alves G, Fiedler W, Guenther E, Nascimento P, Campos MM, Ornellas AA. Determination of telomerase activity in squamous cell carcinoma of the penis. Int. J. Oncol. 18, 67–70 (2001).
264. Schwartz RA. Buschke-Loewenstein tumor. Verrucous carcinoma of the penis. J. Am. Acad. Dermatol. 23, 723–772 (1993).
265. Ouban A, Dellis J, Salup R, Morgan M. Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma. Ann. Clin. Lab. Sci. 33, 101–106 (2003).
266. Saeed S, Keehn CA, Khalil FK, Morgan MB. Immunohistochemical expression of Bax and Bcl02 in penile carcinoma. Ann. Clin. Lab. Sci. 35, 91–96 (2005).
267. Sturm JT, Christenson CE, Vecker JH et al. Squamous cell carcinoma of the anus arising in a giant condyloma acuminatum. Dis. Colon Rectum 18, 147–151 (1975).
268. Johnson DE, Lo RK, Srigley J, Ayala AG. Vererucous carcinoma of the penis. J. Urol. 133, 216–218 (1985).
269. Hull MT, Eble JN, Priest JB, Mulcahy JJ. Ultrastructure of Buschke-Loewenstein tumor. J. Urol. 126, 485–489 (1981).
270. Ikeda R, Kobayashi Y, Shiroma K, Suzuki K, Ueda Y. Telomerase activity in giant condyloma acuminatum. Urol. Int. 65, 220–223 (2000).
271. von Krogh G, Horenblas S. The Management and prevention of premalignant penile lesions. Scand. J. Urol. Nephrol. 205 (Suppl.), 220–229 (2000).
272. Fulton JE, Carter DM, Hurley HJ. Treatment of Bowen’s disease with topical 5-fluorouracil under occlusion. Arch. Dermatol. 97, 178 (1968).
273. Lynch JL. Erythroplasia of Queyrat. Arch. Dermatol. 100, 782 (1969).
274. Huesner JN, Pugh RP. Erythroplasia of Queyrat treated with topical 5-fluorouracil. J. Urol. 102, 595–597 (1969).
275. Lewis RJ, Bendl BJ. Erythroplasia of Queyrat-report of a patient successfully treated with topical 5-fluorouracil. Can. Med. Assoc. J. 104, 148–149 (1971).
276. Goette DK, Elgart M, deVillez RL Erythroplasia of Queyrat. Treatment with topically applied fluorouracil. JAMA 232, 934–937 (1975).
277. Tolia BM, Castro VL, Mouded IM et al. Bowen’s disease of the shaft of the penis. Successful treatment with 5-fluorouracil. Urology 7, 617–619 (1976).
278. Goette DK, Carson TE. Erythroplasia of Queyrat. Treatment with topical 5-fluorouracil. Cancer 38, 1498–1502 (1976).
279. Sturm HM. Bowen’s disease and 5-fluorouracil. J. Am. Acad. Dermatol. 1, 513–522 (1979).
280. Kossow AS, Cotelingham JD, Macfarland F. Bowenoid papulosis of the penis. J. Urol. 125, 124–126 (1980).
281. Arlette JP. Treatment of Bowen’s disease and erythroplasia of Queyrat. Br. J. Dermatol. 149, 43–49 (2003).
282. Sonnex TS, Ralfs IG, Plaza de Lanza M, Dawber RP. Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery. Br. J. Dermatol. 106, 581–584 (1982).
283. Brown MD, Zachary CB, Grekin RC, Swanson NA. Penile tumours: their management by Moh’s micrographic surgery. J. Dermatol. Surg. Oncol. 13, 1163–1167 (1987).
284. Brown MD, Zachary CB, Grekin RC, Swanson NA. Genital tumours: their management by micrographic surgery. J. Am. Acad. Dermatol. 18, 115–122 (1988).
285. Boyton KK, Bjorkman DJ. Argon laser therapy for perianal Bowen’s disease: a case report. Lasers Surg. Med. 11, 385–387 (1991).
286. Knoll LD, Segura JW, Benmson RC Jr, Goellner JR. Bowenoid papulosis of the penis: successful management with neodymium: YAG laser. J. Urol. 139, 1307–1309 (1988).
287. Greenbaum SS, Glogau R, Stegman SJ, Tromovitch TA. Carbon dioxide laser treatment of erythroplasia of Queyrat. J. Dermatol. Surg. Oncol. 15, 747–750 (1989).
288. Petrelli NJ, Cebollero JA, Rodriguez-Bigas M, Mang T. Photodynamic therapy in the management of neoplasms of the perianal skin. Arch. Dermatol. 127, 1436–1438 (1992).
289. Stables GI, Stringer MR, Robinson DJ, Ash DV. Erythroplasia of Queryat treated by topical aminolaevulinic acid photodynamic therapy. Br. J. Dermatol. 140, 514–517 (1999).
290. Harth Y, Hirshovitz B. Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen’s disease with 20% aminolevulinic acid, and exposure to red light and infrared light. Harefuah 134, 602–605 (1998).
291. Lee MR, Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas J. Dermatol. 46, 196–198 (2005).
292. Yang CH, Lee JC, Chen CH, Hui CY, Hong HS, Kuo HW. Photodynamic therapy for Bowenoid papulosis using a novel incoherent light-emitting diode device. Br. J. Dermatol. 149, 1297–1299 (2003).
293. Snoeck R, Van Laethem Y, De Clercq E, De Mauneuge J, Clumeck N. Treatment of a Bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch. Int. Med. 161, 2382–2384 (2001).
294. Calista D. Topical cidofovir for erythroplasia of Queyrat of the glans penis. Br. J. Dermatol. 147, 399–400 (2002).
295. Kaspari M, Gutzmer R, Kiehl P, Dumke P, Kapp A, Brodersen JP. Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat. Dermatology 205, 67–69 (2002).
296. Goorney BP, Polori R. A case of Bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. Int. J. STD AIDS 15, 833–835 (2004).
297. Danielsen AG, Sand C, Weismann K. Treatment of Bowen’s disease of the penis with imiquimod 5% cream. Clin. Exp. Dermatol. 28, 7–9 (2003).
298. Micali G, Nasca MR, Tedeschi A. Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin. Exp. Dermatol. 28, 4–6 (2003).
299. Orengo I, Rosen T, Guill CK. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J. Am. Acad. Dermatol. 47, S225 –S2258 (2002).
300. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J. Am. Acad. Dermatol. 46, 545–548 (2002).
301. Wysocki WM, Komorowski AL, Kolodziejski LS, Wysocka J. Synchronous anal and penile cancers. Int J. Urol. 11, 1139–11341 (2004).
302. Mosconi AM, Roila F, Gatta G, Theodore C. Cancer of the penis. Crit. Rev. Oncol. Hematol. 53, 165–177 (2005).
303. Kroon BK, Horenblas S, Nieweg OE. Contemporary management of penile squamous cell carcinoma. J. Surg. Oncol. 89, 43–50 (2005).
304. Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T. European Association of Urology EUA Guidelines on Penile Cancer. Eur. Urol. 46, 1–8 (2004).
305. Singh I, Khaitan A. Current trends in the management of carcinoma penis – a review. Int. Urol. Nephrol. 35, 215–225 (2003).
306. Micali G, Nasca MR, Innocenzi D, Schwartz RA. Invasive penile carcinoma: a review. Dermatol. Surg. 30, 311–320 (2004).
307. Stancik I, Holtl W. Penile cancer: review of the recent literature. Curr. Opin. Urol. 13, 467–472 (2003).
308. Harden SV, Tan LT. Treatment of localized carcinoma of the penis: a survey of current practice in the UK. Clin. Oncol. (R. Coll. Radiol.) 13, 284–287 (2001).
309. Munro NP, Thomas PJ, Deutsch GP, Hodson NJ. Penile cancer: a case for guidelines. Ann. R. Coll. Surg. Engl. 83, 180–185 (2001).
310. Siow WY, Cheng C. Penile cancer: current challenges. Can. J. Urol. 12, 18–23 (2005).
311. Schoeneich G, Perabo FG, Muller SC. Squamous cell carcinoma of the penis. Andrologia 31 (Suppl. 1), 17–20 (1999).
312. Pietrzak P, Corbishley C, Watkin N. Organ-sparing surgery for invasive penile cancer: early follow-up data. BJU Int. 95, 1253–1257 (2004).
313. Agrawal A, Pai D, Ananthakrishnan N, Smile SR, Ratnakar C. Clinical and sonographic findings in carcinoma of the penis. J. Clin. Ultrasound 28, 399–406 (2000).
314. Lont AP, Besnard AP, Gallee MP, van Tinteren H, Horenblas S. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int. 91, 493–495 (2003).
315. Scardino E, Villa G, Bonomo G et al. Magnetic resonance imaging combined with artificial erection for local staging of penile cancer. Urology 63, 1158–1162 (2004).
316. Agrawal A, Pai D, Ananthakrishnan N, Smile SR, Ratnakar C. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int. 85, 299–301 (2000).
317. McDougal WS, Kirchner FR, Edwards RH, Killion LZ. Treatment of carcinoma of the penis: the case for primary lymphadenectomy. J. Urol. 136, 38–41 (1986).
318. Dexeus FH, Logothetis J, Sella A et al. Combination therapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J. Urol. 146, 1284–1287 (1991).
319. James N. Chemoradiotherapy for penile cancer. In: The Effective Management of Urological Malignancies. Anderson J, Oliver RTD, Miles A (Eds). Aesculapius Medical Press, London, UK (2005).
320. Laniado ME, Lowdell C, Mitchell H, Christmas TJ. Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma fo the penis. BJU Int. 92, 248–250 (2003).
321. Kommu S, Hadway P, Watkin N. Squamous cell carcinoma antigen as a biomarker for penile cancer. BJU Int. 95, 478–479 (2005).
322. Rippentrop JM, Joslyn SA, Konety BR. Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology and end results program. Cancer 101, 1357–1363 (2004).
323. Sanchez-Ortiz RF, Pettaway CA. Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach. Urol. Clin. N. Am. 30, 853–867 (2003).
324. South LM, O’Sullivan JP, Gazet JC. Giant condylomata of Buschke and Lowenstein. Clin. Oncol. 3, 107–115 (1977).
325. Tessler AN, Applebaum SM. The Buschke-Lowenstein tumor. Urology 20, 36–39 (1982).
326. Creasman C, Haas PA, Fox TA Jr., Balazas M. Malignant transformation of anorectal giant condyloma acuminatum (Buschke-Loewenstein tumour). Dis. Colon Rectum 32, 481–487 (1989).
327. Lenk S, Oesterwitz H, Audring H. Laser surgery in superficial penile tumours. Int. Urol. Nephrol. 23, 357–363 (1991).
328. Risse L, Negrier P, Dang PM et al. Treatment of verrucous carcinoma with recombinant α-interferon. Dermatology 190, 142–144 (1995).